Cargando…

Discovery, Optimization, and Characterization of Novel D(2) Dopamine Receptor Selective Antagonists

[Image: see text] The D2 dopamine receptor (D2 DAR) is one of the most validated drug targets for neuropsychiatric and endocrine disorders. However, clinically approved drugs targeting D2 DAR display poor selectivity between the D2 and other receptors, especially the D3 DAR. This lack of selectivity...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xiao, Jingbo, Free, R. Benjamin, Barnaeva, Elena, Conroy, Jennie L., Doyle, Trevor, Miller, Brittney, Bryant-Genevier, Marthe, Taylor, Mercedes K., Hu, Xin, Dulcey, Andrés E., Southall, Noel, Ferrer, Marc, Titus, Steve, Zheng, Wei, Sibley, David R., Marugan, Juan J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Chemical Society 2014
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4315423/ https://www.ncbi.nlm.nih.gov/pubmed/24666157 http://dx.doi.org/10.1021/jm500126s

Ejemplares similares

Discovery, Optimization, and Characterization of Novel Chlorcyclizine Derivatives for the Treatment of Hepatitis C Virus Infection
por: He, Shanshan, et al.
Publicado: (2015)

Discovery of a functionally selective ghrelin receptor (GHSR(1a)) ligand for modulating brain dopamine
por: Gross, J. D., et al.
Publicado: (2022)

Efficacy and Mechanism of Action of Low Dose Emetine against Human Cytomegalovirus
por: Mukhopadhyay, Rupkatha, et al.
Publicado: (2016)

Identification of 4-phenylquinolin-2(1H)-one as a specific allosteric inhibitor of Akt
por: Huang, Bill X., et al.
Publicado: (2017)

Discovery of small molecule inhibitors that effectively disrupt IQGAP1-Cdc42 interaction in breast cancer cells
por: Sayedyahossein, Samar, et al.
Publicado: (2022)

Activation of Relaxin Family Receptor 1 from Different Mammalian Species by Relaxin Peptide and Small-Molecule Agonist ML290
por: Huang, Zaohua, et al.
Publicado: (2015)

Agonist-specific voltage-dependent gating of lysosomal two-pore Na(+) channels
por: Zhang, Xiaoli, et al.
Publicado: (2019)

Adverse Events Associated With the Use of Sipuleucel-T Reported to the US Food and Drug Administration’s Adverse Event Reporting System, 2010-2017
por: Dores, Graça M., et al.
Publicado: (2019)

High-Throughput Multiplexed Quantitation of Protein Aggregation and Cytotoxicity in a Huntington’s Disease Model
por: Titus, Steven A, et al.
Publicado: (2012)

Novel Cryo-EM structures of the D1 dopamine receptor unlock its therapeutic potential
por: Sibley, David R., et al.
Publicado: (2021)

Discovery of small molecule agonists of the Relaxin Family Peptide Receptor 2
por: Esteban-Lopez, Maria, et al.
Publicado: (2022)

DPTIP, a newly identified potent brain penetrant neutral sphingomyelinase 2 inhibitor, regulates astrocyte-peripheral immune communication following brain inflammation
por: Rojas, Camilo, et al.
Publicado: (2018)

Dopamine Receptor Antagonists as New Mode-of-Action Insecticide Leads for Control of Aedes and Culex Mosquito Vectors
por: Nuss, Andrew B., et al.
Publicado: (2015)

Anxiolytic Drug FGIN-1-27 Ameliorates Autoimmunity by Metabolic Reprogramming of Pathogenic Th17 Cells
por: Singh, Anju, et al.
Publicado: (2020)

Dopamine receptor antagonists as potential therapeutic agents for ADPKD
por: Paul, Parama, et al.
Publicado: (2019)

The E(2.65)A mutation disrupts dynamic binding poses of SB269652 at the dopamine D2 and D3 receptors
por: Verma, Ravi Kumar, et al.
Publicado: (2018)

Novel Patient Cell-Based HTS Assay for Identification of Small Molecules for a Lysosomal Storage Disease
por: Geng, Haifeng, et al.
Publicado: (2011)

Association of dopamine-related genetic loci to dopamine D3 receptor antagonist ABT-925 clinical response
por: Bhathena, A, et al.
Publicado: (2013)

High Throughput Screening for Inhibitors of Alpha-Galactosidase
por: Motabar, Omid, et al.
Publicado: (2010)

Roles of dopamine receptors and their antagonist thioridazine in hepatoma metastasis
por: Lu, Meiling, et al.
Publicado: (2015)

M198. INVESTIGATIONAL DOPAMINE ANTAGONISTS FOR THE TREATMENT OF SCHIZOPHRENIA
Publicado: (2020)

Ligand with Two Modes of Interaction with the Dopamine D(2) Receptor–An Induced-Fit Mechanism of Insurmountable Antagonism
por: Ågren, Richard, et al.
Publicado: (2020)

Dopamine regulates pancreatic glucagon and insulin secretion via adrenergic and dopaminergic receptors
por: Aslanoglou, Despoina, et al.
Publicado: (2021)

The effect of a dopamine antagonist on conditioning of sexual arousal in women
por: Brom, Mirte, et al.
Publicado: (2016)

The Dopamine D5 Receptor Is Involved in Working Memory
por: Carr, Gregory V., et al.
Publicado: (2017)

Single exposure of dopamine D1 antagonist prevents and D2 antagonist attenuates methylphenidate effect
por: Claussen, Catherine M, et al.
Publicado: (2015)

c-Abl Activation Linked to Autophagy-Lysosomal Dysfunction Contributes to Neurological Impairment in Niemann-Pick Type A Disease
por: Marín, Tamara, et al.
Publicado: (2022)

High Throughput Screening for Small Molecule Therapy for Gaucher Disease Using Patient Tissue as the Source of Mutant Glucocerebrosidase
por: Goldin, Ehud, et al.
Publicado: (2012)

Structure-Activity Investigation of a G Protein-Biased Agonist Reveals Molecular Determinants for Biased Signaling of the D(2) Dopamine Receptor
por: Chun, Lani S., et al.
Publicado: (2018)

Effects of dopamine D(4 )receptor antagonist on spontaneous alternation in rats
por: Moustgaard, Anette, et al.
Publicado: (2008)

Shared GABA transmission pathology in dopamine agonist- and antagonist-induced dyskinesia
por: Abe, Yoshifumi, et al.
Publicado: (2023)

SAT-035 Small Molecule Allosteric Agonist of Relaxin Receptor Ml290 Demonstrates Antifibrotic Properties in Liver Fibrosis
por: Kaftanovskaya, Elena, et al.
Publicado: (2019)

Activation of the dopamine 1 and dopamine 5 receptors increase skeletal muscle mass and force production under non-atrophying and atrophying conditions
por: Reichart, Deborah L, et al.
Publicado: (2011)

The dopamine D2 receptor antagonist sulpiride modulates striatal BOLD signal during the manipulation of information in working memory
por: Dodds, Chris M., et al.
Publicado: (2009)

Dopamine D(4) Receptor-Selective Compounds Reveal Structure–Activity Relationships that Engender Agonist Efficacy
por: Keck, Thomas M., et al.
Publicado: (2019)

High-throughput screening identified selective inhibitors of exosome biogenesis and secretion: A drug repurposing strategy for advanced cancer
por: Datta, Amrita, et al.
Publicado: (2018)

A challenge to the dopamine orthodoxy in schizophrenia?
por: Norman, Trevor R, et al.
Publicado: (2023)

Synaptamide activates the adhesion GPCR GPR110 (ADGRF1) through GAIN domain binding
por: Huang, Bill X., et al.
Publicado: (2020)

G Protein-Coupled Receptor Kinase 2 Selectively Enhances β-Arrestin Recruitment to the D(2) Dopamine Receptor through Mechanisms That Are Independent of Receptor Phosphorylation
por: Sánchez-Soto, Marta, et al.
Publicado: (2023)

Dopamine D3 Receptor Antagonists as Potential Therapeutics for the Treatment of Neurological Diseases
por: Maramai, Samuele, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_r8nm66plmc5jden66e9frsckib